Compare JD.Com Inc (JD) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs State Street SPDR S&P Biotech ETF — how do they compare? JD.Com Inc trades at $27.09 (market cap $36.62B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: JD.Com Inc is far larger — about 3.6× State Street SPDR S&P Biotech ETF's market cap, and JD.Com Inc pays a 3.72% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| JD | XBI | |
|---|---|---|
Market Cap | $36.62B | $10.11B |
Volume | 6,571,477 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $34.53 | $169.55 |
52-Week Low | $25.19 | $104.99 |
Typical Hold Time | 85 Days | 38 Days |
Enterprise Value | $19.26B | — |
Dividend Yield | 3.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $26.91, down 0.44% on the day, with a bullish technical signal despite mixed moving average indicators. The company shows strong fundamentals with revenue growth to $1.31 trillion in 2025 and consistent earnings beats, though net margins compressed to 1.13%. Recent news highlights JD's potential EU approval for its $2.5 billion Ceconomy acquisition and positive analyst sentiment with 69.6% buy ratings.
JD presents a compelling value opportunity with attractive valuation multiples (P/E 17.9, P/S 0.2) and strong cash position ($234B), though investors face risks from regulatory scrutiny and competitive pressures in China's e-commerce sector. The consensus price target of $35.86 suggests 33% upside potential from current levels.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite an oversold RSI reading. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive news flow around biotech catalysts. Recent articles highlight XBI's biotech focus versus broader healthcare ETFs, with expense ratio comparisons and volatility considerations.
The outlook remains cautious due to technical weakness and high volatility, though sector-specific catalysts like cancer vaccine developments and M&A activity provide potential upside. Key risks include sector volatility, regulatory uncertainty, and competitive ETF offerings with lower fees.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
